 |
 |
 |
 |
|
|
|
|
 |
|
|
 |
|
|
|
|
| |
|||||||||||||||||
|
|
|
|
|
|
|
|||||||||||
|
|||||||||||||||||
|
EID
Home | Ahead of Print | Past
Issues | EID Search | Contact
Us | Announcements | Suggested
Citation | Submit Manuscript
Volume 9, Number 12, December 2003 Visceral Leishmaniasis Treatment, ItalyLuigi Gradoni,* Marina Gramiccia,* and Aldo Scalone* |
|
|
|
 |
|
| Back to article | |
|
Figure 2. Annual proportion of immunocompetent patients with visceral leishmaniasis treated with meglumine antimoniate (MA) or amphotericin B (AmB) in the period 1995–2001. |
|
|
|
|
|
EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z |
|
|
This page last reviewed October 22, 2003 |
|
|
Emerging
Infectious Diseases Journal |
|